Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK ( TheStreet) -- It's time to start focusing on what matters, Jim Cramer told viewers of "Mad Money" Monday. Today he explained the differences between where investors are focusing their attention and where the money is actually being made. Cramer said the markets have been buzzing about the looming U.S. economic "fiscal cliff" for months now, but no one had ever asked the most important question: Where will it cost us? He said that question is important because so far it hasn't been asked. The threat of a fiscal cliff was supposed to rein in consumer spending, but apparently 310 million Americans never got that memo because everything from retail to autos has been bullish. Even the banks are beginning to rebound, with foreclosure levels hitting multi-year lows. Then there's the obsession with tech stocks, the place where innovation and excitement are supposed to live. But Cramer said that outside of the iPad, there's been little innovation as of late. He said the most innovative thing he's seen in tech are the cell tower companies converting themselves into REITs. As for disk drives, memory chips and semiconductors, those stocks have cost investors fortunes. Cramer said the real money is being made in the aforementioned retail and consumer names, companies like Home Depot ( HD), Panera Bread ( PNRA) and Walt Disney ( DIS). Meanwhile, the real innovation has been in biotech, with companies like Abbott Labs ( ABT) and Eli Lilly ( LLY). That's why investors need to keep their focus on what's working, because worrying about the fiscal cliff and investing in most of technology would have just cost them much of their portfolios.
What Makes a Great IPO?It was the best of times for the initial public offering market last week, but the worst of times the week before that. What changed? Cramer said the quality of the companies coming public did, which makes the last two weeks the perfect lesson in what makes a great IPO. Cramer said that last week's IPO of Workday ( WDAY) outperformed because that company is a cloud play with strong revenue growth and a solid management team. Meanwhile, Realogy ( RLGY) was also a fast grower as well as a pure play on a housing recovery.
Kythera Biopharmaceuticals ( KYTH) and Intercept Pharmaceuticals ( ICPT) are two biotechs with big market opportunities and, in the case of Intercept, also have orphan drug protection. Shutterstock ( SSTK) is one of only a few players in its space, said Cramer, while Fleetmatics ( FLTX) is another cloud play like Workday. Compare those successful IPOs to those of two weeks ago, however, and the stories change. Berry Plastics ( BERY) is a commodity plastic container maker with next to no growth. Lifelock ( LOCK) provides identity protection but is seeing increased competition and is not yet profitable. Javelin Mortgage ( JMI) aims to be a REIT, but has no track record to offer investors, while Regulus Therapeutics ( RGLS) is a biotech with no funding. Cramer said its easy to see why this second group of IPOs failed to impress Wall Street.